CPNE2

Across TCGA pan-cancer cohorts, CPNE2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CPNE2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CPNE2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CPNE2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where CPNE2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.263	0.499	.004	24	view →
CCRCC	DFS	Median	III,IV	0.846	0.596	.032	6	view →
LSCC	DFS	Quartile	II,III,IV	0.150	0.766	.038	3	view →
GBM	OS	Quartile	All	0.634	0.422	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CPNE2–PDAC (OS)

Open the PDAC breakdown →